Joseph J. Romano

Columbia University — United States

Medicine · Health Sciences

17h-index1.9kcitations39works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hepatitis C virus research(10), HIV/AIDS drug development and treatment(8), Monoclonal and Polyclonal Antibodies Research(6), interferon and immune responses(5), Chemical Synthesis and Analysis(4)

Publications39 total

Passion and Passionless Love in Dante: From Epistola 3 to the Commedia
Palgrave studies in medieval and early modern medicine·2024
This Strange Creature: Plato and Conversion Experiences
Religions·2021· 1 citedOpen Access
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel
ACS Medicinal Chemistry Letters·2020· 4 citedOpen Access
CCDC 1984118: Experimental Crystal Structure Determination
The Cambridge Structural Database·2020Open Access
Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors
ACS Medicinal Chemistry Letters·2019· 26 citedOpen Access
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases
Journal of Medicinal Chemistry·2019· 65 citedOpen Access
Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity
Nature·2019· 43 citedOpen Access
Design of amidobenzimidazole STING receptor agonists with systemic activity (vol 564, pg 439, 2018)
Nature·2019
Mr. Blue by Myles Connolly
American Catholic Studies·2019
Design of amidobenzimidazole STING receptor agonists with systemic activity
Nature·2018· 806 cited
Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel
ACS Medicinal Chemistry Letters·2018· 35 citedOpen Access
Synthesis of ( S )-3-amino-benzo[ b ][1,4]oxazepin-4-one via Mitsunobu and S N Ar reaction for a first-in-class RIP1 kinase inhibitor GSK2982772 in clinical trials
Tetrahedron Letters·2017· 5 cited
P2‐Quinazolinones and Bis‐Macrocycles as New Templates for Next‐Generation Hepatitis C Virus NS3/4a Protease Inhibitors: Discovery of MK‐2748 and MK‐6325
ChemMedChem·2015· 23 cited
ChemInform Abstract: The Synthetic Preparation of Naturally‐Occurring Aromatase Inhibitors, Morachalcone A (Ia), Isogemichalcone B (Ib), and Isogemichalcone C (Ic).
ChemInform·2014
Novel Quinoline-Based P2–P4 Macrocyclic Derivatives As Pan-Genotypic HCV NS3/4a Protease Inhibitors
ACS Medicinal Chemistry Letters·2014· 25 citedOpen Access
The synthetic preparation of naturally-occurring aromatase inhibitors, morachalcone A, isogemichalcone B, and isogemichalcone C
Tetrahedron·2013· 16 cited
Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2–P4 linkers
Bioorganic & Medicinal Chemistry Letters·2012· 11 citedOpen Access
Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease
Bioorganic & Medicinal Chemistry Letters·2012· 6 cited
Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor
ACS Medicinal Chemistry Letters·2012· 201 citedOpen Access
Discovery of MK-1220: A Macrocyclic Inhibitor of Hepatitis C Virus NS3/4A Protease with Improved Preclinical Plasma Exposure
ACS Medicinal Chemistry Letters·2011· 32 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

John A. McCauley(13), Nigel J. Liverton(13), Michael T. Rudd(11), Charles McIntyre(11), Kimberly J. Bush(10), Steven S. Carroll(10), Jillian DiMuzio(10), Mark W. Stahlhut(10), David B. Olsen(10), John W. Butcher(9), Joseph P. Vacca(9), Robert W. Marquis(8), Christine Fandozzi(8), John F. Mehlmann(7), John Bertin(7), M. Katharine Holloway(7), Kevin F. Gilbert(7), Donald J. Graham(7), Nicole Trainor(7), Adam K. Charnley(6)